These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34098057)

  • 1. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.
    Simental-Mendía LE; Sánchez-García A; Linden-Torres E; Simental-Mendía M
    Diabetes Res Clin Pract; 2021 Jul; 177():108899. PubMed ID: 34098057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.
    Simental-Mendía LE; Sánchez-García A; Linden-Torres E; Simental-Mendía M
    Br J Clin Pharmacol; 2021 Nov; 87(11):4140-4149. PubMed ID: 33835520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glucagon-like peptide-1 receptor agonists on renal function: A meta-analysis of randomized controlled trials.
    Simental-Mendía M; Linden-Torres E; Sánchez-García A; Sahebkar A; Simental-Mendía LE
    Br J Clin Pharmacol; 2022 Aug; 88(8):3566-3576. PubMed ID: 35277985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
    Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
    Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
    Mazidi M; Karimi E; Rezaie P; Ferns GA
    J Diabetes Complications; 2017 Jul; 31(7):1237-1242. PubMed ID: 28479155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huixing L; Di F; Daoquan P
    Clin Ther; 2023 Jan; 45(1):17-30. PubMed ID: 36604209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
    Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
    BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Fibrate Treatment on Circulating Adipokine Levels: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Simental-Mendía LE; Simental-Mendía M; Sahebkar A; Atkin SL; Jamialahmadi T
    Arch Med Res; 2024 Feb; 55(2):102957. PubMed ID: 38266418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Scatena A; Giannini S; Andreozzi F; Sesti G; Mannucci E
    J Endocrinol Invest; 2017 Nov; 40(11):1251-1258. PubMed ID: 28569363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.
    Rezaei S; Tabrizi R; Nowrouzi-Sohrabi P; Jalali M; Atkin SL; Al-Rasadi K; Jamialahmadi T; Sahebkar A
    Can J Gastroenterol Hepatol; 2021; 2021():8936865. PubMed ID: 34805029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
    Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
    Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review.
    Elnour AA; Al Hajri N; El Khidir IY; AlAmoodi A; Ahmed SA; Sadeq A
    Curr Diabetes Rev; 2020; 16(8):820-832. PubMed ID: 32442089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.
    Hu W; Song R; Cheng R; Liu C; Guo R; Tang W; Zhang J; Zhao Q; Li X; Liu J
    Front Endocrinol (Lausanne); 2022; 13():927859. PubMed ID: 35898463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
    Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
    Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
    Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
    Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.